Business
While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Moncef Slaoui was fired as chairman of the board of directors of Galvani Bioelectronics following allegations of sexual harassment and inappropriate conduct.
Merck Treasurer Caroline Litchfield will become the company’s new chief financial officer. She takes over the role for Robert M. Davis, who will become company president and chief executive officer upon the retirement of current CEO Kenneth C. Frazier.
It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
Targeted immunotherapy company Asher Bio launched today with a $55 million Series A round led by Third Rock Ventures, aiming to move its lead engineered interleukin-2 (IL-2) therapy into human testing next year.
Zenas BioPharma announced it has launched a cross-border biopharmaceutical company based in both China and the U.S.
AlloVir and Abeona Therapeutics have both appointed new chief executive officers. Here’s a look.
Jerusalem’s clinical-stage pharmaceutical company Oramed Pharmaceuticals is forming a joint venture with Premas Biotech to develop novel oral COVID-19 vaccine candidates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
XyloCor Therapeutics closed an additional $22.6 million in its oversubscribed Series A financing round that will support the development of its lead gene therapy program for patients with refractory angina, a coronary artery disease.
A giant in the world of oncology has fallen. José Baselga, whose research paved the way for new treatments in different types of cancer, died Sunday.